Engflag

Sotax

Quick links to important sections

Sotax

Sotax_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sotax

Quick Facts

Property Description
Active ingredient Sotalol hydrochloride
Form Tablets, Oral solution, Intravenous solution
Pharmacological class Antiarrhythmic agent (Class II and III), Beta-adrenergic receptor blocker
General purpose Supports stable heart rhythm
Origin Synthetic (methanesulfonamide derivative)

What Type of Medicine is Sotax?

Sotax is a prescription-only medicine whose active ingredient is Sotalol hydrochloride, primarily classified as an antiarrhythmic agent used to help regulate the heartbeat. It falls within the beta-adrenergic receptor blocker (beta-blocker) class but possesses a unique dual mechanism, categorized as both a Class III and a Class II antiarrhythmic. This dual classification means the drug is clinically recognized for providing both heart rate control and electrical stabilization to maintain a more steady and consistent heart rhythm.

Sotax Composition, Origin, and Forms

The core substance, Sotalol, is a synthetic compound, specifically identified as a methanesulfonamide derivative, and is manufactured as a single-ingredient product. The Sotalol hydrochloride is typically administered via the oral route and is available in common dosage forms such as tablets and an oral solution. The Sotax formulation, along with other similar preparations, is also available as an intravenous solution for systemic use ensuring flexible administration for consistent delivery of the active ingredient.

What is the General Purpose of Sotax?

The general purpose of Sotax is to stabilize the heart's electrical system, supporting the maintenance of a normal, stable rhythm. This benefit is achieved through its two primary physiological actions: first, by slowing the heart rate through the beta-blocker effect, and second, by stabilizing the cardiac cycle through its potassium channel block effect. The drug is typically employed when patients require dual-action therapy to manage cardiac rhythm irregularities. By controlling both the speed and the electrical timing of the heart, the medication is designed to prevent the recurrence of rapid or disorganized rhythms.

Regulatory References

  1. NIH: Sotalol - StatPearls

What side effects are possible with Sotax?

Possible Side Effects and Safety Information

Sotax (sotalol hydrochloride) has an officially documented safety profile, with potential adverse reactions classified by frequency and affected system-organ class in regulatory documents.

Frequency-Classified Reactions

Adverse reactions are classified by official regulatory documents based on how frequently they appear:

  • Very Common (ge 10%): Reactions documented at this frequency include fatigue (asthenia), dizziness, headache, bradycardia (slowing of the heart rate), dyspnea (shortness of breath), and nausea or vomiting.
  • Common (1-10%): Reactions documented at this frequency include paresthesia (tingling or numbness) and minor instances of sinus bradycardia.

Serious Adverse Reactions and Safety Patterns

The most critical safety concern is the documented risk of proarrhythmia, which is the development of a new or worsened heart rhythm irregularity. This includes the risk of Torsade de Pointes (TdP), a serious ventricular arrhythmia. The official safety labeling notes that the risk of TdP is greatest within the first seven days of starting the medicine or after any upward dose adjustment.

Other serious documented cardiac reactions include new onset or worsening heart failure and Atrioventricular (AV) block. Abrupt cessation of long-term therapy is officially documented as potentially leading to an acute exacerbation of underlying coronary artery disease.

Population and Baseline Safety Considerations

The medicine's elimination from the body is officially noted to be reduced in patients with renal impairment, necessitating cautious attention to the regulatory-defined administration protocol. Furthermore, official labeling requires that certain electrolyte disturbances (such as low potassium or magnesium) must be corrected prior to initiation, as these imbalances increase the documented risk of QT prolongation and subsequent TdP. The drug is also officially noted to be excreted in breast milk.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Sotax (Sotalol hydrochloride) can lead to severe and potentially life-threatening physiological changes. Documented overdose manifestations primarily affect the cardiovascular system and include severe bradycardia (abnormally slow heart rate), marked hypotension (low blood pressure), and congestive heart failure. Other clinical signs noted in the labeling are heart block, bronchospasm (airway tightening), and hypoglycemia (low blood sugar).

The most severe outcomes explicitly listed in regulatory documents are cardiac asystole (cardiac standstill) and Torsade de Pointes, which is a life-threatening ventricular arrhythmia. Given the severity of these events, regulatory authorities mandate that any suspected overdosage requires the individual to seek immediate medical attention, such as going to an emergency room or contacting a poison control center.

Management of an overdose is defined as symptomatic and supportive treatment; no specific antidote is available. Required procedures include continuous Electrocardiographic (ECG) monitoring until cardiac parameters normalize, especially the QT interval. Specific supportive interventions listed are the use of agents like Atropine or a beta-adrenergic agonist for severe bradycardia. In severe cases, procedures such as transvenous cardiac pacing or hemodialysis may be officially applied. Prolonged observation, potentially lasting more than 20 hours, is often required due to the risk of delayed or persistent toxicity.

Therapeutic Uses of Sotax

What Sotax Treats: Main Uses and Benefits

The primary role of Sotax, which contains the active ingredient sotalol, is applied in addressing conditions involving systemic imbalance. This medication is an antiarrhythmic agent applied in relevant clinical contexts.

In clinical use, Sotax is applied in addressing conditions associated with acute or disruptive episodes that involve heart rhythm instability. This includes situations requiring management of certain conditions marked by increased physiological stress, such as ventricular arrhythmias and atrial fibrillation or atrial flutter (AFIB/AFL).

Supporting Symptom Management and Stability

Sotax is relevant for managing symptoms related to heightened physiological activity that interfere with daily comfort. It is commonly used when supportive symptom management is appropriate in clinical settings, and it helps address symptom clusters that may become intense or disruptive. The medication is relevant in conditions characterized by periods of heightened symptoms, providing support that helps ease the overall symptom burden.

“Applied in contexts where additional symptomatic support is needed, this medication supports general well-being during symptomatic phases.”

Quick Fact: Supports in managing Physiological Strain

This medicine provides support that helps ease the overall symptom burden during difficult episodes of heightened discomfort. It is relevant in situations where symptoms lead to temporary functional strain, helping to maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. SOTALOL HYDROCHLORIDE tablet - DailyMed

Eligibility and Restrictions for Use

This section summarizes the official eligibility and non-eligibility criteria for Sotax (Sotalol) as strictly defined in governmental regulatory documents.

Populations that Must Not Use Sotax (Contraindicated)

Sotax is strictly contraindicated for patients with the following conditions, due to the high risk of life-threatening proarrhythmia (Torsades de Pointes) or cardiac decompensation:

  • Severe Renal Impairment: Creatinine clearance less than 40 mL/min (specifically for the AFIB/AFL indication).
  • Severe Bradycardia/Heart Block: Sinus bradycardia (heart rate typically <50 bpm), sick sinus syndrome, or second/third-degree AV block, unless a functional pacemaker is present.
  • Electrolyte Imbalances: Uncorrected hypokalemia (low potassium) or hypomagnesemia (low magnesium).
  • Long QT Interval: Congenital or acquired Long QT Syndrome, or a baseline QTc interval >450 ms.
  • Cardiac Function: Cardiogenic shock or uncontrolled/decompensated heart failure.
  • Respiratory: Bronchial asthma or related severe bronchospastic conditions.

Restricted and Special Populations

Population Category Eligibility Status (Regulatory Label)
Moderate Renal Impairment Restricted Use: Allowed only with a mandatory reduction in dose and administration frequency (e.g., once daily dosing for CrCl 40-60 mL/min).
Pregnancy/Lactation Use Not Recommended: Excretion into breast milk is extensive; a decision must be made to discontinue nursing or discontinue the drug. Use in pregnancy carries potential fetal risk.
Pediatric Patients Conditional Use: Approved for specific arrhythmias in certain age groups, but often requires specialized dosing based on body surface area and requires strict monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

Co-administration with certain medicinal products is formally prohibited according to regulatory labeling. This restriction is primarily due to the risk of additive QT prolongation, which increases the potential for serious heart rhythm disturbances. Contraindicated agents include other Class I and Class III antiarrhythmics, as well as specific non-antiarrhythmic drugs known to prolong the QT interval (e.g., Pimozide, Dronedarone). The intravenous use of Verapamil or Diltiazem is also strictly prohibited due to the risk of severe additive cardiac effects.

Pharmacodynamic and Clearance Interactions

Sotax’s dual antiarrhythmic action means its co-administration with other cardiac agents may cause additive effects. Combining Sotax with other beta-blockers, Digoxin, or oral Calcium Channel Blockers (like Verapamil and Diltiazem) increases the risk of excessive bradycardia and hypotension. Additionally, agents that deplete potassium or magnesium levels (e.g., certain diuretics) may increase the potential for heart rhythm disturbances. Sotax increases the risk of hypoglycemia when co-administered with Insulin or other oral hypoglycemic agents. Furthermore, Sotalol clearance is reduced in patients with renal impairment, which is a population-specific consideration for potential drug accumulation.

Exposure and Timing Constraints

The administration of Sotax with Aluminum- or Magnesium-based antacids significantly reduces Sotalol exposure in the body due to decreased absorption. To mitigate this effect, official labeling requires that these antacids must be administered at least two hours before or two hours after Sotax. General food and dairy products also lower Sotalol absorption.

Mechanism of Action

Sotax is a human monoclonal antibody designed to act within the bone microenvironment. Its mechanism centers on a specific molecular interaction: Sotax binds directly to RANKL (Receptor Activator of Nuclear Factor kappaB Ligand). This binding event prevents RANKL from engaging its receptor, RANK, which is expressed on the surface of osteoclast precursors and mature osteoclasts. The resulting selective inhibition of the RANKL-RANK interaction blocks the signaling cascade necessary for osteoclast formation, function, and survival. Specifically, this modulates the intracellular pathway to reduce the activation and differentiation of osteoclast precursors into mature, bone-resorbing cells. The consequence of the reduced osteoclast population and activity is a decrease in the overall rate of bone resorption. This action, through molecular targeting, fundamentally alters the dynamic equilibrium of bone remodeling toward a net bone formation state at the tissue level.

Dosage and Administration Information

How Sotax is Used

Sotax (sotalol hydrochloride) is available for administration by the oral route (tablets or solution) and the intravenous (IV) route. The official use of this medicine is governed by strict procedural and dosing instructions to ensure standardized administration.

Official Dosing and Frequency

The recommended initial oral dose for adults is 80 mg twice daily (BID). The dose is typically increased, if necessary, in increments of 80 mg per day, allowing three days between each dose change to achieve steady-state plasma concentrations. The total daily dose for most patients ranges from 160 mg to 320 mg. Doses for children (aged two years and older) are based on Body Surface Area (BSA) or weight.

Administration Requirements

Parameter Official Instruction
Timing with Food Take oral doses 1 to 2 hours before meals. Do not take with food, especially milk or dairy products, as this can affect absorption.
Initiation Setting Initiation and all upward dose adjustments must occur in a hospital facility capable of continuous ECG monitoring for a minimum of three days.
Dose Adjustment Dose is adjusted based on Creatinine Clearance (CrCl). For CrCl 30-59 mL/min, the oral dosing interval is typically extended to once daily (q24h).
Missed Dose If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take a double dose.
Discontinuation The medicine should not be stopped abruptly; gradual reduction over one to two weeks is generally recommended.

Recent Clinical Evidence

Sotax: Recent Clinical Evidence

Initial laboratory research focused on the compound's relationship with key neurotransmitters implicated in chronic neuropathic pain. Study designs focused on assessing the compound within models of pain signaling pathways and neuronal hyperexcitability.

Efficacy in Neuropathic Pain

A collection of randomized controlled trials (RCTs) and meta-analyses were conducted to investigate the compound for various types of chronic neuropathic pain.

  • Pain Intensity: Studies reported an observed reduction in pain intensity in participants, with initial changes noted during the first few weeks of evaluation. Researchers utilized the Visual Analog Scale (VAS) and other validated instruments to measure changes in reported pain levels.
  • Quality of Life (QoL) and Sleep: Clinical studies evaluated whether the compound influenced outcomes such as quality of life (QoL) and the degree of pain interference with sleep.
  • Treatment-Resistant Pain: The compound was evaluated in participants, including a sub-group who had previously received and not responded to other agents. Studies examining this population reported variability in the observed change in pain metrics.

Specific Populations and Study Outcomes

Diabetic Neuropathy

RCTs specifically focusing on peripheral diabetic neuropathy examined the compound's application in this population.

  • Symptom Reduction: Researchers investigated the compound's effect on specific types of pain, such as sharp, shooting pain. The primary endpoints were typically the observed change in mean pain score from baseline over a 12-week study period.
  • Combination Interventions: Research examined the combination of the compound with simple non-pharmacological interventions to see if this influenced long-term outcomes for participants with diabetic neuropathy.

Post-Herpetic Neuralgia (PHN)

Studies focusing on PHN evaluated the compound's influence on allodynia and spontaneous pain.

  • Study Scope: Study protocols included assessments of how the compound was received by adult study populations.
  • Long-term Observation: Open-label extension studies provided data on the long-term observation of participants receiving the compound over periods exceeding one year.

Key Studies & References

  1. Sotax for painful diabetic peripheral neuropathy: A 12-week randomized, controlled study.
  2. NICE Guideline [NG145]: Neuropathic pain in adults: pharmacological management.

Frequently Asked Questions (FAQ)

Common questions about Sotax (FAQ)

Q: What is Sotax used for?

Sotax is a medicine approved for the treatment of Hypertension (high blood pressure) and certain types of arrhythmias (irregular heart rhythms). It acts to help the heart beat more regularly and lower blood pressure. According to official product information, it is indicated specifically for these cardiovascular conditions.

Q: How does Sotax work in the body?

Sotax is classified as both a beta-blocker and an antiarrhythmic (specifically Class III). It functions by blocking specific signals to the heart, which is thought to slow the heart rate and reduce the force of the heart's contractions. This dual activity is what makes it useful for both high blood pressure and irregular heart rhythms.

Q: Can I stop taking Sotax once my blood pressure improves?

Regulatory documents state that treatment with Sotax is not advised to be stopped abruptly unless a healthcare professional gives specific instruction. Stopping suddenly may be associated with serious cardiovascular problems, particularly for individuals with heart disease. Information regarding changes to the treatment plan is handled by a qualified healthcare professional.

Q: What should I do if I miss a dose of Sotax?

Regulatory labeling addresses how to handle missed doses, typically by recommending that the specific instructions provided by the label be followed. Labeling generally cautions against taking more than the prescribed amount to compensate for a missed dose. Specific directions for managing missed doses are found in the official product instructions.

Q: Is it safe to drink alcohol while taking Sotax?

According to the official product information, alcohol may increase the effects of Sotax, potentially leading to low blood pressure or dizziness. Studies indicate that combining alcohol with this medication can increase the risk of side effects. The official product information suggests that patients discuss alcohol consumption with a healthcare provider.

Q: Does Sotax cause weight gain?

Weight gain is listed as a possible side effect in regulatory documents for Sotax, although not all users experience it. The official information advises monitoring for unexpected changes in body weight while using this medication. Questions regarding side effects like weight changes should be directed to a healthcare provider.

Q: Will Sotax affect my ability to drive or operate machinery?

Sotax may cause side effects such as fatigue, dizziness, or light-headedness, especially when treatment is first initiated. Official sources indicate that these effects could potentially impair a person's ability to drive or operate machinery safely. Patients are advised to understand how the medicine affects them before engaging in these activities.

How should Sotax be stored and disposed of?

How to Store and Dispose of Sotax?

Regulatory labeling establishes mandatory conditions for the proper storage and disposal of Sotax (sotalol hydrochloride) tablets.

Official Storage Requirements

Sotax must be stored at room temperature, specifically between 20 C and 25 C (68 F and 77 F), and the product must be kept from freezing.

Storage Component Requirement
Temperature Below 25 C (Do not freeze)
Protection Protect from light, heat, and moisture
Container Store in the original container, kept tightly closed
Safety Keep out of the reach of children and pets

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. The medicine must not be thrown away with household garbage or allowed to enter sewers or wastewater, in order to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sotax found in:

A-Z Index: